Statin and fibrate associated myopathy: Study of eight patients

Arquivos de Neuro-Psiquiatria

Volumn 62, Issue 2 A, 2004, Pages 257-261

  Siqueira Carvalho, Alzira A ^a,b   Poti Lima, Ürsula Waleska ^a   Valiente, Raul Alberto ^a  

^a HSM   (Brazil)

^b NONE   (Brazil)

Author keywords

Creatine kinase; Fibrates; Muscle biopsy; Myopathy; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CREATINE KINASE; ETOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ARTHRALGIA; ARTICLE; CHRONIC DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA; INFLAMMATORY INFILTRATE; MALE; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROMUSCULAR DISEASE; RHABDOMYOLYSIS; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 2642560526     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2004000200013     Document Type: Article

References (18)

1. Langford NJ, Kendall MJ. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect? J Clin Ph Therap 2001;26:391-395.
2. Galiana J, Marchán E, Montés I, Pato S. Miopatías tóxicas en relacíon con la administración de hipolipidemiantes: son los fármacos los únicos responsables? Rev Clin Esp 1995;195:620-622.
3. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001;175:486-489.
4. Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG Co A reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Bri J Clin Pharmacol 1996;42:333-337.
5. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
6. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol 2002;40:163-171.
7. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002;13:415-420.
8. Ucar M, Mjorndal T, Dahlqvist R. HMG CoA reductase inhibitors and myotoxicity. Drug Safety 2000;22:441-457.
9. Gaist D, Rodriguez LAG, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a Population-based follow-up study. Epidemiology 2001;12:565-569.
10. Dubowitz V. Muscle biopsy: a practical Approach. London: Bailliere Tindall, 1985.
11. Argov Z, Squier W. Toxic and iatrogenic disorders. In Karpati G(ed). Structural and molecular basis of skeletal muscle diseases, Basel: ISN Neuropath Press, 2000:245-249.
12. Philips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
13. Bardosi A, Scheidt P, Goebel HH. Mitochondrial myopathy: a result of clofibrate/etofibrate treatment? Acta Neuropathol (Berl) 1985;68:164-168.
14. England FGJ, Walsh CJ, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatement with the HMGCoA reductase inhibitors: simvastatin and pravastatin. Aust NZ J Med 1995;25:374-375.
15. Vianna MAAG, Marie SKN, Mendonça LLF, et al. Miopatia por droga hipolipidêmica: a propósito de um caso clínico. Rev Bras Reumatol 1997;37:232-236.
16. Shoubridge EA, Molnar MJ. Oxidative phosphorilation defects. In Karpati G (ed). Structural and molecular basis of skeletal muscle diseases, Basel: ISN Neuropath Press: 2000:202-213.
17. Giordano N, Senesi M, Matti G, et al. Polymyositis associated with simvastatin. Lancet 1997;349:1600-1601.
18. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992;327:649-650.